# High-Level Overview
Reveleer is an AI-powered healthcare software platform that enables value-based care (VBC) programs for health plans and risk-bearing providers.[1] The company specializes in consolidating fragmented workflows across clinical data retrieval, risk adjustment, quality improvement, and member management—critical functions that healthcare organizations struggle to manage efficiently across multiple point solutions.[1]
Reveleer serves the healthcare insurance industry, including Medicare Advantage, ACA Marketplace, and Medicaid sectors.[3] The platform uses natural language processing (NLP) and artificial intelligence to automate the review of structured and unstructured patient data, identifying opportunities for better diagnosis and missed interventions while helping organizations optimize performance on value-based contracts.[2] By centralizing these operations, Reveleer enables providers and health plans to boost productivity, enhance care quality, and improve financial outcomes in an increasingly complex value-based care environment.
# Origin Story
Reveleer was founded in 2009 (originally as Health Data Vision) and is headquartered in Glendale, California.[3] The company was built by a multidisciplinary leadership team with deep expertise in healthcare, technology, and business operations, including Jay Ackerman as Chief Executive Officer & President and Omar Salah as President of Clinical Intelligence.[1]
A pivotal moment came in 2021, when Oak HC/FT invested in the company, recognizing the growing market demand for a comprehensive value-based care solution.[2] At that time, Reveleer had a strong commercialized product and diverse customer base but was overly focused on retrospective medical record review, missing critical end-to-end capabilities. This investment catalyzed a transformation strategy combining internal innovation with strategic acquisitions. The company's first major acquisition was Dynamic Health Care Systems in 2022, a move that proved transformational by adding critical risk adjustment capabilities and rounding out Reveleer's vision for a complete, end-to-end product.[2] Today, Reveleer employs between 201 and 500 people, reflecting its scale as a major player in healthcare software.[1]
# Core Differentiators
# Role in the Broader Tech Landscape
Reveleer is positioned at the intersection of two powerful healthcare trends: the shift toward value-based care models and the adoption of AI for clinical operations. As healthcare systems face mounting pressure to control costs while improving outcomes, value-based contracts have become the industry standard—yet most organizations lack integrated tools to manage them effectively.[2] Reveleer addresses this fragmentation by consolidating workflows that were previously scattered across multiple vendors.
The timing is critical. Healthcare organizations are simultaneously grappling with budget constraints and workforce shortages, making automation and AI adoption essential rather than optional.[3] Reveleer's platform directly tackles these pain points by automating medical record retrieval, coding, and clinical review—functions that traditionally consume significant manual labor. By surfacing clinical insights through AI rather than requiring human chart review, the company enables leaner teams to achieve better outcomes.
Beyond its direct customers, Reveleer influences the broader healthcare ecosystem by demonstrating how AI can solve practical, operational challenges in healthcare—not just theoretical ones. The company's focus on transparency (evidence-linked insights) and provider integration (bi-directional EHR connections) sets a standard for how healthcare AI should be deployed: as a tool that augments clinical teams rather than replacing them.
# Quick Take & Future Outlook
Reveleer is well-positioned to capture significant market share as value-based care becomes the dominant reimbursement model across Medicare, Medicaid, and commercial insurance. The company's acquisition strategy—demonstrated by the Dynamic Health Care Systems deal—suggests management will continue consolidating fragmented point solutions into its platform, creating a defensible, integrated offering that competitors will struggle to replicate.
The next frontier for Reveleer likely involves deepening AI capabilities to move beyond retrospective analysis toward predictive interventions, and expanding internationally as value-based care models gain traction outside the U.S. As healthcare organizations increasingly recognize that AI-driven automation is essential for value-based care success, Reveleer's comprehensive platform and clinical credibility position it as a category leader in healthcare operations technology.
Reveleer has raised $78.0M in total across 5 funding rounds.
Reveleer's investors include Access Biotechnology, B Capital Group, Crosscut Ventures, Endeavor Venture Funds, Neotribe Ventures, Oak HC/FT, Science, Tachyon Ventures, Upfront Ventures, Vince Thompson.
Reveleer has raised $78.0M across 5 funding rounds. Most recently, it raised $65.0M Venture Round in December 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2021 | $65.0M Venture Round | Access Biotechnology, B Capital Group, Crosscut Ventures, Endeavor Venture Funds, Neotribe Ventures, Oak HC/FT, Science, Tachyon Ventures, Upfront Ventures, Vince Thompson | |
| Oct 1, 2019 | $6.0M Series C | B Capital Group, Crosscut Ventures, Neotribe Ventures, Science, Upfront Ventures, Vince Thompson | |
| Sep 1, 2018 | $3.0M Series B | B Capital Group, Crosscut Ventures, Neotribe Ventures, Science, Upfront Ventures, Vince Thompson | |
| May 1, 2014 | $1.0M Series A | B Capital Group, Crosscut Ventures, Neotribe Ventures, Science, Upfront Ventures, Vince Thompson | |
| Jan 1, 2013 | $3.0M Series A | B Capital Group, Crosscut Ventures, Neotribe Ventures, Science, Upfront Ventures, Vince Thompson |
